Objective: The purpose of this study was to determine whether there are differences in depression characteristics among premenopausal, perimenopausal, and postmenopausal women with major depressive disorder. This study also evaluated these differences between postmenopausal women with major depressive disorder who are taking and not taking hormone therapy.
T he sex difference in prevalence of major depressive disorder (MDD) is well established, with rates about twice as high in women than in men. 1<3 A number of studies have also demonstrated differences in the clinical presentation of MDD in women versus men, including presenting symptoms, course of illness features, comorbidity, and functional impairment. 4<8 Moreover, sex differences in treatment response, both to antidepressants and psychotherapy, have been reported in some but not all studies. 4,9<16 Reproductive hormonal factors are likely to contribute to the sex differences in depression, which begin around the time of puberty and persist through midlife. 2, 17 Some women appear to be particularly susceptible to developing depression during times of hormonal fluctuation, including the premenstrual phase of the menstrual cycle, the postpartum period, and the perimenopause. 18<20 Fluctuations in estrogen and progesterone are known to affect neurotransmitters involved in depression, including both serotonin and norepinephrine. 21, 22 In addition, some studies have suggested that menopause status may influence antidepressant treatment response, particularly with tricyclic antidepressants and selective serotonin reuptake inhibitors. 9, 11, 12, 14, 15, 23 Despite the clear influences of hormonal factors on depression in some women, to the best of our knowledge, no study has examined whether the clinical presentation of depression in women differs according to their menopause status. Furthermore, no study has assessed the possible effects of hormone therapy on the characteristics of depression in postmenopausal women. A recent report 24 did find that hormonal contraceptives may affect depression severity and symptom profile in premenopausal women. Moreover, several studies have found that estrogen is efficacious in treating perimenopausal depression. 25<27 Others have suggested that hormone therapy may enhance antidepressant treatment response in postmenopausal women who are treated with selective serotonin reuptake inhibitors. 15 ,28<30 Hence, postmenopausal women with depression who are taking hormone therapy may present differently than those who are not.
The purpose of this report was to determine whether the presentation of depression in women differs according to menopause status or to whether the woman is taking or not taking hormone therapy. To determine the former, we compared baseline sociodemographic and clinical characteristics among premenopausal, perimenopausal, and postmenopausal women with MDD who were not taking hormone therapy. To determine the latter, we evaluated differences in depression characteristics in postmenopausal women who were and were not taking hormone therapy.
METHODS
The current study used data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, 31, 32 a National Institute of Mental HealthYsupported study that provided an opportunity to examine differences in the presentation of depression as a function of menopause status in women seeking treatment for a major depressive episode. The goal of STAR*D was to define prospectively which of several treatments are most effective for participants with nonpsychotic MDD and who report an unsatisfactory clinical outcome to an initial and, if necessary, subsequent treatment(s). The study protocol was developed according to the principles of the Declaration of Helsinki. All risks, benefits, and adverse events associated with STAR*D were explained to participants, who provided written informed consent before study participation. The population and methods of STAR*D are described in detail elsewhere. 31, 32 Study population STAR*D enrolled 4,041 participants from July 2001 through April 2004. To achieve the goal of recruiting a broadly representative group of participants with MDD, STAR*D enrolled patients from 18 primary and 23 psychiatric care clinical sites across the United States that serve either the public or private sectors. Advertising for participants was not permitted because it tends to enroll a less representative study sample. 33 Every effort was made to recruit a broad spectrum of participants representing all racial groups and both sexes.
Inclusion/exclusion criteria
The inclusion criteria were broad so as to acquire a sample representative of individuals with MDD who would receive medication or psychotherapy in everyday practice. Eligible participants were outpatients aged 18 to 75 years with nonpsychotic MDD who scored 14 or higher on the 17-item Hamilton Rating Scale for Depression (HRSD 17 ) 34, 35 and for whom antidepressant treatment was deemed appropriate by the treating clinician. Participants with suicidal ideation were eligible as long as outpatient treatment was deemed clinically safe. Participants with most general medical conditions (GMCs) were eligible; however, persons with medical contraindications that precluded randomization to treatments used in the first two steps of the study were excluded.
Participants with a lifetime history of schizophrenia, schizoaffective or bipolar disorder, or MDD with psychotic features were excluded, as were those with a primary diagnosis of anorexia nervosa, bulimia, or obsessive-compulsive disorder because these primary psychiatric conditions required a different initial treatment. 36 Participants with currently active and clinically significant substance abuse were eligible as long as inpatient care was not required clinically at study entry. Those with active substance dependence who required detoxification were not eligible for reasons of medical safety. Participants with severe, unstable concurrent psychiatric conditions likely to require hospitalization within 6 months of study entry were also ineligible.
Participants were excluded if they had an established, welldocumented history of nonresponse or clear intolerability in the current major depressive episode to one or more of the protocol treatments delivered at an adequate dose. Participants taking concomitant anxiolytics or sedative hypnotics could enter the study as long as their clinician determined that the antidepressant treatments in the protocol were appropriate and safe. Participants were excluded if they were currently receiving a targeted psychotherapy aimed at their depression; they could participate if they had not responded to such psychotherapy and subsequently terminated it before study enrollment or if they were receiving counseling or therapy for other problems. Participants who were breastfeeding or pregnant or intended to become pregnant within 9 months of enrollment were also excluded.
Assessments
Clinical research coordinators (CRCs) at each of 14 regional centers were trained and certified in implementing the treatment protocol and in data collection methods. After written informed consent at the screening/baseline visit was obtained, participants were evaluated by the CRC. Sociodemographic and clinical information was collected, as were prior course of illness, current and past substance abuse, prior suicide attempts, current GMCs, and history of treatment in the current major depressive episode. The CRC completed the HRSD 17 (at baseline to establish inclusion/exclusion criteria) and the Quick Inventory of Depressive SymptomatologyV Clinician-Rated. 37, 38 Current GMCs were assessed using the Cumulative Illness Rating Scale (CIRS), 39<41 and the presence or absence of 11 axis I psychiatric disorders was assessed using the Psychiatric Diagnostic Screening Questionnaire (PDSQ). 42, 43 A research outcomes assessor called participants for a telephone interview within 72 hours of the baseline visit to complete the HRSD 17 and the 30-item Inventory of Depressive SymptomatologyVClinician-Rated (IDS-C 30 ). 38, 44 Also, within 72 hours of enrollment, a telephonic interactive voice response system was used to collect the 16-item Quick Inventory of Depressive SymptomatologyVSelf-rated (QIDS-SR 16 ) 37,38 for assessment of depression severity, as well as the following measures of quality of life and functioning: the 12-item Short-Form Health Survey (SF-12), 45 the 16-item Quality of Life Enjoyment and Satisfaction Questionnaire, 46 and the five-item Work and Social Adjustment Scale. 47 
Group assignment/definition of menopause status
Menopause status was determined based on both current age and the participant's response to the following question: BIs the patient postmenopausal or posthysterectomy, or male?[ A woman was classified as premenopausal if she was younger than 40 years. Of those classified as premenopausal, 49 (4.74%) answered yes to the above question (indicating that they were postmenopausal or posthysterectomy). These women were still included in the premenopausal group because of the very low prevalence (1%-2%) of naturally occurring menopause in women younger than 40 years. Those in this age group who were posthysterectomy but still had ovaries were likely to still be premenopausal, and those who also had both ovaries removed were likely to be taking menopause hormone therapy and would thus be excluded from the analyses. Women who were at least 40 years old and who reported not being postmenopausal or posthysterectomy were classified as perimenopausal. Finally, women who were at least 40 years old and reported being postmenopausal or posthysterectomy were operationally defined as postmenopausal. A small number of these women may have had a hysterectomy without ovariectomy and were still cycling. Women who had either experienced natural menopause or undergone a hysterectomy were included in the study, with the exception of those women taking hormone therapy.
Of the 4,041 participants enrolled, 62.7% (n = 2,532) were women. Because administration of hormone therapies such as hormonal contraceptives and menopause hormone therapy could affect the presentation of depressive and menopause symptoms, women taking these medications (n = 636 women: 71 progesterone, 147 estrogen, 302 combination, 116 unknown/ other) were excluded from the analyses comparing premenopausal, perimenopausal, and postmenopausal women. Of the remaining 1,896 women, 4 were excluded because of missing information about age or menopause status. Thus, the analyses regarding menopause status were conducted with a sample of 1,892 women. Of these, 950 (50.1%) were classified as premenopausal, 380 (20.0%) were classified as perimenopausal, and 562 (29.6%) were classified as postmenopausal ( Fig. 1A) .
Regarding the comparison with postmenopausal women by hormone therapy status, of the total number of eligible women enrolled in STAR*D (n = 2,532), 768 were postmenopausal. Of these, 35 (4.5%) could not be classified into either group. Thus, the analyses regarding hormone therapy status were conducted with a sample of 737 postmenopausal women. Of these, 171 (22.3%) were taking hormone therapy and 562 (73.2%) were not taking hormone therapy (Fig. 1B) .
Statistical analyses
Descriptive statistics are presented as percentages for categorical variables and as means and SDs for continuous variables. W 2 tests and both parametric and nonparametric analysis of variance methods were used to compare the distribution of discrete and continuous, respectively, sociodemo-graphic and clinical characteristics across menopause status. After adjusting for baseline sociodemographic and clinical characteristics that differed across menopause status, regression models (linear for continuous measures and logistic regression for binary measures) were used to assess the independent effect of menopause status on symptom severity, depressive features, functioning, quality of life, and presence of psychiatric comorbidities, and the significance level from a likelihood ratio test is presented. If significant differences were identified after adjustment, post hoc comparisons were made using a Bonferroni correction.
W 2 tests and both parametric and nonparametric analysis of variance methods were similarly used to compare the distribution of discrete sociodemographic and clinical characteristics across those women taking and not taking hormone therapy. After adjusting for baseline sociodemographic and clinical characteristics that differed across menopause status, regression models (linear for continuous measures and logistic regression for binary measures) were used to assess the independent effect of hormone therapy on symptom severity, depressive features, quality of life, functioning, presence of depressive symptoms, and presence of psychiatric comorbidities, with menopause status entered into the model as a two-level design variable. A P value less than 0.05 indicated a significant difference in all analyses, except for the post hoc analyses, for which a P value of less than 0.0167 indicated a significant difference. Table 1 shows the sociodemographic and baseline clinical characteristics of the study sample by menopause status. Most of the postmenopausal women were seen in primary care settings, whereas most of the premenopausal and perimenopausal women were seen in psychiatric care settings.
RESULTS

Sociodemographic and baseline characteristics
The average ages of premenopausal, perimenopausal, and postmenopausal women were 29.4 T 5.9, 45.0 T 4.0, and 54.6 T 7.9 years, respectively.
Several characteristics of depression history differentiated the three menopause status groups. Specifically, premenopausal and perimenopausal women were more likely to have a positive family history of depression (premenopausal, 58%; perimenopausal, 63%; postmenopausal, 51%; P = 0.0008) and were approximately twice as likely to report a past suicide attempt than were postmenopausal women (premenopausal, 23%; perimenopausal, 20%; postmenopausal, 12%; P G 0.0001). Premenopausal women had the youngest age of onset of their first depressive episode and postmenopausal women had the oldest age of onset (premenopausal, 19 [4.3] ; P = 0.0008). Postmenopausal women were the most likely to present with anxious features (premenopausal, 48%; perimenopausal, 44%; postmenopausal, 55%; P = 0.0057). The differences found in QIDS-SR 16 scores and anxious features were no longer statistically significant after adjustment for differences in baseline sociodemographic and clinical characteristics. Postmenopausal women showed higher mental (premenopausal, 24.7 [8.2] ; perimenopausal, 26.0 [8.7] ; postmenopausal, 28.8 [9.2] ; P G 0.0001) and lower physical (premenopausal, 52.0 [10.3] ; perimenopausal, 49.9 [11.9] ; postmenopausal, 43.4 [11.9] ; P G 0.0001) functioning on the SF-12, although after adjustment, only the difference in SF-12 physical functioning remained significant (P G 0.0001), with the postmenopausal group showing significantly lower physical functioning than did both the premenopausal and perimenopausal groups (post hoc comparisons P G 0.0010 for both pairwise comparisons). Table 3 shows individual depressive symptoms measured by the IDS-C 30 Post hoc tests were performed where adjusted P values were less than 0.05 and revealed a significant difference between the perimenopausal and postmenopausal groups (P G 0.0001) and the premenopausal and postmenopausal groups (P G 0.0001).
Profile of depressive symptoms
for these symptoms to determine the significant differences between individual groups. Perimenopausal women were less likely to have irritability and were more likely to have early-morning insomnia than were premenopausal women. Postmenopausal women were more likely to have suicidal ideation, sympathetic arousal, and gastrointestinal symptoms than were premenopausal women and less likely to have a decreased appetite and have irritability. Perimenopausal women were less likely to have suicidal ideation than were postmenopausal women. Table 4 provides the rates of psychiatric comorbidity as a function of menopause status. Premenopausal women were more likely to have a comorbid diagnosis of obsessivecompulsive disorder (premenopausal, 17%; perimenopausal, 12%; postmenopausal, 12%; P = 0.0116), social phobia (premenopausal, 38%; perimenopausal, 27%; postmenopausal, 24%; P G 0.0001), drug abuse (premenopausal, 8%; perimenopausal, 5%; postmenopausal, 3%; P = 0.0020), bulimia (premenopausal, 19%; perimenopausal, 13%; postmenopausal, 13%; P = 0.0012), and generalized anxiety (premeno-pausal, 28%; perimenopausal, 24%; postmenopausal, 22%; P = 0.0335) than were the other groups. After adjustment, none of these differences in psychiatric comorbidity remained significant.
Psychiatric comorbidity
Comparison of postmenopausal women taking versus not taking hormone therapy
The baseline sociodemographic and clinical characteristics of postmenopausal women by hormone therapy status are presented in Table 5 . Women taking hormone therapy were significantly less likely to be Hispanic (nonhormone, 20%; hormone, 10%; P = 0.0031); were more likely to be white (nonhormone: white, 71%; black, 23%; other, 6%; hormone: white, 83%; black, 15%; other, 2%; P = 0.0031), to be married (nonhormone, 35%; hormone, 47%; P = 0.0066), and to have private insurance (nonhormone, 48%; hormone, 61%; P = 0.0110); and had more years of education (nonhormone, 12.3 [3.9] y; hormone, 13.2 [3.4] y; P = 0.0025). Women taking hormone therapy were also more likely to have recurrent depression (nonhormone, 69%; hormone, 83%; P = 0.0006) and had, on average, greater medical comorbidity on the CIRS (nonhormone, 3.9 [2.4]; hormone, 4.5 [2.4] ; P = 0.0016). We found no significant differences between the two groups with regard to the severity of depression on the HRSD 17 (nonhormone, 20.4 [6.7] ; hormone, 20.0 [6.9]; P = 0.5230) or the presence of atypical features (nonhormone, 17%; hormone, 14%; P = 0.3998); however, after adjustment for baseline sociodemographic and clinical differences, those taking hormone therapy were less likely to have melancholic features (OR, 0.53; 95% CI, 0.30-0.93; P = 0.0289). Women taking hormone therapy had better physical functioning on the SF-12 (nonhormone, 43.4 [11.9] ; hormone, 45.7 [12.2] ; P = 0.0379), which remained significant (A = j2.72 [j4.72, j0.73], P = 0.007) after adjustment for baseline sociodemographic and clinical differences ( Table 6 ). Symptom profiles were similar between the two groups, except that even after adjustment for baseline sociodemographic and clinical differences, women taking hormone therapy were significantly more likely to endorse lack of involvement in activities (OR, 2.02; 95% CI, 1.09-3.75; P = 0.0266) and less likely to endorse sympathetic arousal (OR, 0.62; 95% CI, 0.40-0.97; P = 0.0359; Table 7 ). With regard to psychiatric comorbidities on the PDSQ (Table 8) , women taking hormone therapy were significantly less likely to report agoraphobia (nonhormone, 14%; hormone, 8%; P = 0.0400), although this difference was no longer significant after adjustment.
DISCUSSION
To the best of our knowledge, this is the first study to examine the influence of menopause status on the presentation of MDD in women and the first to examine the effect of hormone therapy on the characteristics of major depression in postmenopausal women.
Our finding that postmenopausal women have more general medical comorbidity, an older age of onset, and less likelihood of family history of depression or past suicide attempt suggests that their depression may be related more to general medical comorbidity, hormonal factors, and/or aging than to a lifelong depressive disorder. After adjustment for baseline differences, we found several differences in symptom profiles among premenopausal, perimenopausal, and postmenopausal women. Our finding of more irritability in premenopausal women may reflect the influence of the menstrual cycle on the presentation of depression, because many women experience premenstrual worsening of depression or other Analyses adjusted for race, ethnicity, family history of depression, attempted suicide, setting, chronicity, age at onset of first MDE, monthly total income, and CIRS total score. premenstrual mood changes, of which irritability is the most common. 48 It was surprising that postmenopausal women reported more suicidal ideation, particularly given the similarity of their severity of illness to the other groups and their less frequent history of suicide attempt. One could speculate that this increased suicidal ideation is related to their greater likelihood of being widowed or divorced, which may reflect a lack of social support, and their lower level of resources given their lower income and less private insurance. To examine whether marital status explained the finding, we compared mean score of the suicidal ideation item from the QIDS-SR 16 across marital status groups and found no statistically significant difference in the scores. Our finding of a greater likelihood of sympathetic arousal, gastrointestinal symptoms, and lower physical functioning in postmenopausal women, characteristics which were present even after adjustment for differences in general medical comorbidity, may be a reflection of age, as these symptoms were also noted to increase with age in a study by Husain et al, 49 who conducted a recent analysis of age-related characteristics of depression that also used the STAR*D population for its study sample. However, an independent effect of hormones is suggested by the fact that postmenopausal women in the study taking hormone therapy had a lower rate of sympathetic arousal and higher physical functioning; this is also consistent with findings in premenopausal women taking versus not taking hormonal contraceptives in another report from the STAR*D study. 24 Previous reports suggest that women commonly present with atypical depressive features, such as hypersomnia and hyperphagia. 4, 5, 7, 50 Interestingly, we found no difference in the presence of atypical or melancholic features of depression by menopause status, with about 20% of women in each group showing each of these subtypes. Although hypersomnia was more common in premenopausal women than in the other two groups, the difference was no longer significant after adjustment. We did find that early-morning insomnia was less common and decreased appetite was more common in premenopausal women; however, it is important to note that in all three of the menopause status groups, midnocturnal awakening was the most common sleep disturbance and decreased appetite was more common than increased appetite. It is also notable that anxious depression was the most common subtype among all three groups and was seen most frequently in postmenopausal women, although the difference by menopause status was no longer significant after adjustment.
In addition to differences in the presentation of depression by menopause status, we also found that depression in postmenopausal women may be influenced by whether concomitant hormone therapy is being taken. The women in our study who were taking hormone therapy were more likely to be white, non-Hispanic, or married, with more years of education and private insurance. The higher educational level in women taking hormone therapy is consistent with the literature 51 before the publication of the Women's Health Initiative results, 52 which is when our study was initiated. Women taking hormone therapy were also more likely to have a recurrent course of depression and greater general medical comorbidity. The greater general medical comorbidity in women taking hormone therapy probably results in increased contact with healthcare providers and, therefore, increased opportunities for hormone therapy to be prescribed.
Comparing symptom profiles after adjustment for baseline differences, women taking hormone therapy reported better physical functioning, fewer melancholic features, less sympathetic arousal, and more lack of involvement in activities compared with women not taking hormone therapy. The better physical functioning, less melancholia, and less sympathetic arousal (ie, less anxiety) are consistent with the beneficial effects on sleep, energy, mood, and quality of life that have been described with hormone therapy. 53 However, the similar overall severity of depression in those taking and not taking hormone therapy is consistent with literature showing that estrogen is not a treatment for major depression in postmenopausal women, 54 although it also suggests that hormone therapy does not worsen depressive symptoms. There are several limitations to this study. The sample was restricted to outpatients with nonpsychotic MDD and may not be generalizable to all depressed women. It was not a random sample of depressed women as seen in epidemiologic studies; however, we did use broad inclusion criteria, recruited women from primary and psychiatric care sites across the United States, and had appropriate minority representation. Hence, our sample was probably representative of depressed women seeking care in outpatient settings. Another limitation was the definition of menopause status used, which was based on a combination of age and a question about menopause status and hysterectomy status. More detailed questions about irregular or skipped menstrual cycles and timing of cessation of cycles would have enabled more exact classification of women as premenopausal, perimenopausal, or postmenopausal. In addition, we do not know the timing of the onset of depression in postmenopausal women in relation to their beginning or stopping hormone therapy, information that may have further clarified the effect of hormone therapy on depressive symptom presentation. It is also true thatVat least to some extentVage and menopause status covary and some of the differences identified may have more to do with age differences than with reproductive hormonal status. Much of our data rely on self-report and patient recall, which may be unreliable. Finally, the self-report PDSQ was used to diag-nose comorbid axis I psychiatric disorders although it is a screening tool.
CONCLUSIONS
In conclusion, depressive episode presentation in women may be influenced by menopause status as well as postmenopausal use of hormone therapy. The differences reported should be considered in the clinical evaluation and management of women with depression. Future analyses will examine the impact of menopause status and hormone therapy on antidepressant treatment response. 
